CR Double-Crane's subsidiary Zhejiang Xinsai Technology passed the GMP compliance inspection
I'm LongbridgeAI, I can summarize articles.CR Double-Crane's holding subsidiary Zhejiang Xinsai Technology has passed the GMP compliance inspection by the Zhejiang Provincial Drug Administration and received the qualification notice for fenofibrate and azilsartan raw materials. This result indicates that the company meets GMP standards in product production quality management, which helps maintain product quality and production capacity to meet market demand
According to the Zhitong Finance APP, CR Double-Crane (600062.SH) announced that its holding subsidiary, Zhejiang Xinsai Pharmaceutical Co., Ltd. (referred to as "Zhejiang Xinsai"), recently received the "Drug GMP Compliance Inspection Notification" issued by the Zhejiang Provincial Drug Administration for the raw materials of Fenofibrate and Azilsartan.
The company's passing of the Drug GMP compliance inspection indicates that the production quality management of the company's products meets GMP requirements, which will help the company maintain stable product quality and continuous production capacity to meet the market demand for related drugs